Compare Stocks: VERA, KYMR, PRAX, and PTGX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
KYMR Kymera Therapeutics	$117.39 +0.1%	$114.16	$42.22 ▼ $130.05	$9.76B	1.96	710,163 shs	378,565 shs
PRAX Praxis Precision Medicines	$351.81 -0.9%	$338.92	$37.19 ▼ $392.70	$9.82B	2.76	366,440 shs	175,349 shs
PTGX Protagonist Therapeutics	$145.72 -2.1%	$141.19	$54.50 ▼ $160.81	$9.43B	1.8	476,558 shs	501,296 shs
VERA Vera Therapeutics	$35.89 +2.6%	$35.86	$21.96 ▼ $56.05	$2.59B	0.96	2.04 million shs	1.18 million shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
KYMR Kymera Therapeutics	0.00%	-0.64%	+10.32%	+58.36%	+171.11%
PRAX Praxis Precision Medicines	0.00%	+2.05%	-4.96%	+38.51%	+655.77%
PTGX Protagonist Therapeutics	0.00%	+0.96%	-0.31%	+49.64%	+150.77%
VERA Vera Therapeutics	0.00%	+4.97%	+12.09%	+11.15%	+56.32%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
KYMR Kymera Therapeutics	$117.39 +0.1%	$114.16	$42.22 ▼ $130.05	$9.76B	1.96	710,163 shs	378,565 shs
PRAX Praxis Precision Medicines	$351.81 -0.9%	$338.92	$37.19 ▼ $392.70	$9.82B	2.76	366,440 shs	175,349 shs
PTGX Protagonist Therapeutics	$145.72 -2.1%	$141.19	$54.50 ▼ $160.81	$9.43B	1.8	476,558 shs	501,296 shs
VERA Vera Therapeutics	$35.89 +2.6%	$35.86	$21.96 ▼ $56.05	$2.59B	0.96	2.04 million shs	1.18 million shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
KYMR Kymera Therapeutics	0.00%	-0.64%	+10.32%	+58.36%	+171.11%
PRAX Praxis Precision Medicines	0.00%	+2.05%	-4.96%	+38.51%	+655.77%
PTGX Protagonist Therapeutics	0.00%	+0.96%	-0.31%	+49.64%	+150.77%
VERA Vera Therapeutics	0.00%	+4.97%	+12.09%	+11.15%	+56.32%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
KYMR Kymera Therapeutics	2.88	Moderate Buy	$128.70	9.63% Upside
PRAX Praxis Precision Medicines	2.95	Moderate Buy	$585.95	66.55% Upside
PTGX Protagonist Therapeutics	2.89	Moderate Buy	$147.13	0.97% Upside
VERA Vera Therapeutics	2.86	Moderate Buy	$81.15	126.12% Upside

Current Analyst Ratings Breakdown

Latest VERA, KYMR, PRAX, and PTGX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/1/2026	PTGX Protagonist Therapeutics	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$153.00 ➝ $180.00
9/1/2026	PTGX Protagonist Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$178.00 ➝ $190.00
8/31/2026	PTGX Protagonist Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$175.00 ➝ $182.00
8/31/2026	PTGX Protagonist Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
8/31/2026	PTGX Protagonist Therapeutics	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
8/31/2026	PTGX Protagonist Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$167.00 ➝ $170.00
8/31/2026	KYMR Kymera Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$135.00 ➝ $170.00
8/27/2026	KYMR Kymera Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$116.00 ➝ $151.00
8/24/2026	PRAX Praxis Precision Medicines	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/24/2026	KYMR Kymera Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/21/2026	PRAX Praxis Precision Medicines	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$470.00 ➝ $575.00

(Data available from 9/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
KYMR Kymera Therapeutics	$39.21M	248.94	N/A	N/A	$18.15 per share	6.47
PRAX Praxis Precision Medicines	$8.55M	1,148.83	N/A	N/A	$48.03 per share	7.32
PTGX Protagonist Therapeutics	$46.02M	204.90	N/A	N/A	$13.01 per share	11.20
VERA Vera Therapeutics	N/A	N/A	N/A	N/A	$5.66 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
KYMR Kymera Therapeutics	-$311.35M	-$3.24	N/A	N/A	N/A	-285.33%	-21.22%	-19.21%	11/3/2026 (Estimated)
PRAX Praxis Precision Medicines	-$303.27M	-$12.93	N/A	N/A	N/A	N/A	-34.15%	-32.42%	11/9/2026 (Estimated)
PTGX Protagonist Therapeutics	-$130.15M	$1.03	141.48	N/A	N/A	29.40%	12.03%	11.23%	11/5/2026 (Estimated)
VERA Vera Therapeutics	-$299.61M	-$5.86	N/A	N/A	N/A	N/A	-84.13%	-66.79%	11/4/2026 (Estimated)

Latest VERA, KYMR, PRAX, and PTGX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/10/2026	Q2 2026	VERA Vera Therapeutics	-$1.58	-$1.52	+$0.06	-$1.52	$1.28 million	N/A
8/6/2026	Q2 2026	PRAX Praxis Precision Medicines	-$3.67	-$2.87	+$0.80	-$2.87	$1.25 million	N/A
8/5/2026	Q2 2026	KYMR Kymera Therapeutics	-$0.7126	-$0.62	+$0.0926	-$0.62	$32.78 million	$65.00 million
8/5/2026	Q2 2026	PTGX Protagonist Therapeutics	$2.27	$2.29	+$0.02	$2.29	$212.03 million	$213.48 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
KYMR Kymera Therapeutics	N/A	N/A	N/A	N/A	N/A
PRAX Praxis Precision Medicines	N/A	N/A	N/A	N/A	N/A
PTGX Protagonist Therapeutics	N/A	N/A	N/A	N/A	N/A
VERA Vera Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
KYMR Kymera Therapeutics	N/A	10.34	10.34
PRAX Praxis Precision Medicines	N/A	15.73	15.73
PTGX Protagonist Therapeutics	N/A	21.71	21.71
VERA Vera Therapeutics	0.18	10.92	10.92

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
KYMR Kymera Therapeutics	N/A
PRAX Praxis Precision Medicines	67.84%
PTGX Protagonist Therapeutics	98.63%
VERA Vera Therapeutics	99.21%

Insider Ownership

Company	Insider Ownership
KYMR Kymera Therapeutics	15.98%
PRAX Praxis Precision Medicines	3.00%
PTGX Protagonist Therapeutics	5.19%
VERA Vera Therapeutics	15.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
KYMR Kymera Therapeutics	170	83.15 million	69.86 million	Optionable
PRAX Praxis Precision Medicines	110	27.92 million	27.08 million	Optionable
PTGX Protagonist Therapeutics	120	64.71 million	61.35 million	Optionable
VERA Vera Therapeutics	40	72.06 million	60.61 million	Optionable

VERA, KYMR, PRAX, and PTGX Headlines

Recent News About These Companies

Vera Therapeutics (NASDAQ:VERA) CEO Sells $649,720.00 in Stock

September 4 at 5:07 PM | marketbeat.com

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 4 at 4:05 PM | globenewswire.com

Braidwell LP Purchases 40,900 Shares of Vera Therapeutics, Inc. $VERA

September 3 at 4:39 AM | marketbeat.com

Vera Therapeutics to Participate at Upcoming Investor Conferences

September 1, 2026 | globenewswire.com

AN2 Therapeutics Presents Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera at the Society of Hematologic Oncology (SOHO) 2026 Annual ...

August 31, 2026 | joplinglobe.comJ

Vera Therapeutics (NASDAQ:VERA) Trading Down 5.2% - What's Next?

August 27, 2026 | marketbeat.com

Vera Therapeutics, Inc. $VERA Stock Position Raised by Odyssean LLC

August 26, 2026 | marketbeat.com

Vera Therapeutics Sees Unusually Large Options Volume (NASDAQ:VERA)

August 25, 2026 | marketbeat.com

Vera Therapeutics, Inc. (VERA) Stock Price, News, Quote & History - Yahoo Finance

August 25, 2026 | finance.yahoo.com

Vera Therapeutics (NASDAQ:VERA) Stock Price Up 6.2% - Here's What Happened

August 24, 2026 | marketbeat.com

Vera Therapeutics (NASDAQ:VERA): What Could Drive the Next Move?

August 19, 2026 | kalkinemedia.comK

J.P. Morgan Sticks to Their Buy Rating for Vera Therapeutics (VERA)

August 19, 2026 | theglobeandmail.com

Vera Therapeutics, Inc. (NASDAQ:VERA) Receives Consensus Rating of "Moderate Buy" from Analysts

August 19, 2026 | marketbeat.com

Bank of America Corp DE Has $23.72 Million Stake in Vera Therapeutics, Inc. $VERA

August 18, 2026 | marketbeat.com

Vera Therapeutics: FDA's eGFR Analysis Supports A Speculative Buy

August 17, 2026 | seekingalpha.com

Wedbush Reiterates Neutral Rating for Vera Therapeutics (NASDAQ:VERA)

August 17, 2026 | marketbeat.com

Vera Therapeutics (NASDAQ:VERA) Shares Gap Up - Here's Why

August 14, 2026 | marketbeat.com

HC Wainwright Has Positive Estimate for VERA Q3 Earnings

August 14, 2026 | marketbeat.com

Analysts Offer Insights on Healthcare Companies: Clinigence Holdings (NUTX), Vera Therapeutics (VERA) and Solid Biosciences (SLDB)

August 12, 2026 | theglobeandmail.com

Vera Therapeutics (NASDAQ:VERA) Given New $90.00 Price Target at HC Wainwright

August 12, 2026 | marketbeat.com

E. Ohman J or Asset Management AB Acquires 42,787 Shares of Vera Therapeutics, Inc. $VERA

August 12, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

VERA, KYMR, PRAX, and PTGX Company Descriptions

Kymera Therapeutics NASDAQ:KYMR

$117.39 +0.11 (+0.09%)

As of 09/4/2026 04:00 PM Eastern

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Praxis Precision Medicines NASDAQ:PRAX

$351.81 -3.34 (-0.94%)

As of 09/4/2026 04:00 PM Eastern

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.

Protagonist Therapeutics NASDAQ:PTGX

$145.72 -3.08 (-2.07%)

As of 09/4/2026 04:00 PM Eastern

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Vera Therapeutics NASDAQ:VERA

$35.89 +0.90 (+2.57%)

As of 09/4/2026 04:00 PM Eastern

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VERA, KYMR, PRAX, and PTGX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VERA, KYMR, PRAX, and PTGX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VERA, KYMR, PRAX, and PTGX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

VERA, KYMR, PRAX, and PTGX Company Descriptions

Kymera Therapeutics NASDAQ:KYMR

Praxis Precision Medicines NASDAQ:PRAX

Protagonist Therapeutics NASDAQ:PTGX

Vera Therapeutics NASDAQ:VERA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VERA, KYMR, PRAX, and PTGX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VERA, KYMR, PRAX, and PTGX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VERA, KYMR, PRAX, and PTGX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

VERA, KYMR, PRAX, and PTGX Company Descriptions

Kymera Therapeutics NASDAQ:KYMR

Praxis Precision Medicines NASDAQ:PRAX

Protagonist Therapeutics NASDAQ:PTGX

Vera Therapeutics NASDAQ:VERA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools